Drug Trial Radar · NCT04807335
Study of CT001 in Healthy Volunteers
Last checked: Nov 19, 2026Latest source record: Aug 24, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
14
Actual
Start
Mar 17, 2021
Primary completion
Jun 2, 2021
Study completion Jun 2, 2021
Sponsor
- Lead sponsor
- Cessatech A/SIndustry
- Sponsor type
- Industry
- Collaborators
- Dantrials Aps; Smerud Medical Research International AS
- First posted
- Mar 19, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A phase 1, three arms, cross over comparison study to evaluate bioavailability, pharmacokinetics and safety of intra nasal CT001 in healthy volunteers.
Conditions
- Bioavailability
Interventions
CT001Drug
nasal spray
KetamineDrug
iv single dose
sufentanilDrug
iv single dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- concentration of CT001 in the bloodTime frame: baseline, 3, 5, 10, 15, 30, 60, 90, 180, 240 minutes and 6, 9, 24, 32, 48 hours after dose
- Total amount of CT001 in the blood over timeTime frame: baseline, 3, 5, 10, 15, 30, 60, 90, 180, 240 minutes and 6, 9, 24, 32, 48 hours after dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Dantrials
Copenhagen, DK, Denmark
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.